Nilotinib Accord

Nilotinib, the active ingredient in Nilotinib Accord, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Nilotinib Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company follows stringent quality standards and provides regulatory documentation to support import and clinical use. Our global distribution network ensures timely delivery to authorized healthcare facilities.

Nilotinib targets the BCR‑ABL tyrosine kinase pathway and is indicated for specific leukemic conditions. - Chronic phase chronic myeloid leukemia (CML): reduces disease progression and improves survival. - Accelerated phase CML: achieves hematologic and cytogenetic responses in patients with advanced disease. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when used in combination therapy.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools often occurring early in therapy. - Rash: skin erythema or pruritus. - Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Pancreatitis: abdominal pain with elevated enzymes. - Severe hepatic injury: marked increase in liver transaminases. - Hematologic toxicity: neutropenia, thrombocytopenia, or anemia.

When prescribing Nilotinib, clinicians should observe several safety measures to minimize risks. - Cardiac monitoring: obtain baseline ECG and repeat periodically due to QT‑prolongation risk. - Liver function: assess transaminases before initiation and monitor during treatment. - Electrolyte balance: correct potassium and magnesium deficiencies to reduce cardiac events. - Drug interactions: avoid concomitant strong CYP3A4 inhibitors and QT‑prolonging agents. - Pregnancy and lactation: use only if benefits outweigh potential risks; safety data are limited. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and light.

Nilotinib’s pharmacokinetics can be altered by several co‑administered medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase nilotinib exposure. - QT‑prolonging drugs (e.g., amiodarone, sotalol): additive risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: reduce nilotinib absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may require dose adjustment and close monitoring. - H2‑blockers or proton‑pump inhibitors: can affect gastric pH and influence drug bioavailability. - Diuretics that cause electrolyte loss: monitor potassium and magnesium levels to prevent QT prolongation. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib concentrations, reducing efficacy.